There were 1,393 press releases posted in the last 24 hours and 438,381 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Catalyst Biosciences Announces Positive Interim Data from a Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image